Kathy Bernstein
Gerontology · New Orleans, LANPI 1144642091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$687
- Abbott$620
- Novo Nordisk$608
- BETA Bionics, Inc.$590
- Medtronic$480
- Lilly USA, LLC$456
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,60697%
- Education$882%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 24 | $687 |
| Abbott | 15 | $620 |
| Novo Nordisk | 27 | $608 |
| BETA Bionics, Inc. | 11 | $590 |
| Medtronic | 6 | $480 |
| Lilly USA, LLC | 15 | $456 |
| Mannkind Corporation | 10 | $286 |
| Xeris Pharmaceuticals, Inc. | 13 | $267 |
| Bayer | 14 | $231 |
| Insulet Corporation | 5 | $217 |
| Pfizer | 9 | $171 |
| Amgen | 6 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $122 |
| Zealand Pharma US, Inc. | 4 | $109 |
| Boehringer Ingelheim | 5 | $84 |
| Tandem Diabetes Care, Inc. | 1 | $79 |
| Ascendis Pharma Endocrinology Inc | 4 | $73 |
| Calliditas Therapeutics US Inc. | 3 | $68 |
| Amneal Pharmaceuticals LLC | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| AstraZeneca | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Ardelyx, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Verona Pharma, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Embecta Corp. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,753 in reported general payments places this provider in the 90th percentile of 64 gerontology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 461 | $534,322 |
| JardianceEmpagliflozin | 230 | $264,617 |
| OzempicSemaglutide | 241 | $248,867 |
| TrulicityDulaglutide | 62 | $70,802 |
| FarxigaDapagliflozin Propanediol | 43 | $37,716 |
| ProliaDenosumab | 21 | $37,252 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $26,645 |
| TradjentaLinagliptin | 29 | $25,379 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 47 | $24,345 |
| FiaspInsulin Aspart (Niacinamide) | 23 | $21,523 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $21,248 |
| JanuviaSitagliptin Phosphate | 22 | $20,269 |
| Gvoke Hypopen 2-PackGlucagon | 22 | $16,301 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $15,751 |
| RybelsusSemaglutide | 14 | $13,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $456 | $614,319595 claims |
| Boehringer IngelheimJardiance, Tradjenta | $84 | $289,996259 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $608 | $289,036289 claims |
| AstraZenecaFarxiga | $60 | $37,71643 claims |
| AmgenProlia | $128 | $37,25221 claims |
| MerckJanuvia | $13 | $20,26922 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $63 | $16630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 gerontology providers in Louisiana.
Other gerontology in New Orleans
- Denise OverbyNew Orleans$369
- Susan Duhon-JohnstonNew Orleans$116
- Sydnie JeantyNew Orleans$93
- Jodie HarrisonSlidell$12K
- Whitney StevensSlidell$10K
- Rebekah HendryBossier City$6K
- Jessica GaubertBaton Rouge$6K
- Katrina GipsonMonroe$6K
- Jennifer HarveySlidell$5K
- Maureen PoeSulphur$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.